Smith & Nephew Plc CFO Anne-Françoise Nesmes to step down

Smith & Nephew plc

Smith & Nephew (LON:SN, NYSE: SNN), the global medical technology company, has announced that Anne-Françoise Nesmes has informed the Board of her intention to step down as Chief Financial Officer during the second quarter of 2024, on a date to be agreed. The Board has initiated an external search for her successor.

Deepak Nath, Chief Executive Officer, said: “I would like to thank Anne-Françoise for her leadership and significant contribution to Smith & Nephew. She was instrumental in helping the Group navigate the financial challenges of the pandemic and in laying the foundation for our transformation under the 12-point plan. On a personal note, I have been very grateful for her support and counsel which I know will continue over the coming months. When the time comes, she will leave Smith & Nephew with our best wishes.”

Roberto Quarta, Chair of the Board, said: “On behalf of the Board I would like to thank Anne-Françoise for her important contribution at Smith & Nephew and for the early communication of her intention to step-down, which will support an orderly succession. She has been a highly valued member of the Board and a strong and dynamic leader of the business, and we wish her well for the future.”

Anne-Françoise Nesmes, said: “It has been a privilege to work alongside Deepak and the leadership team and I have every confidence that Smith & Nephew is on a path to stronger performance. Given our progress, I feel now is the right moment to reflect and consider my next professional challenge. I would like to thank my colleagues for their strong support and dedication, and remain fully committed to continuing our work together until I leave next year.”

Further announcements regarding Anne-Françoise’s leaving date and the appointment of her successor will be made in due course.

Share on:

Latest Company News

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans.

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion.

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership.

Smith & Nephew Plc 12-Point Plan increasingly delivering better financial performance

Smith & Nephew reports strong financial results for 2024 with significant revenue and profit growth, driven by innovation and strategic restructuring.

Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.

Smith & Nephew Plc transforming into a higher growth and more profitable business

Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.

    Search

    Search